Trade Vericel Corp - VCEL CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.16
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02129 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.02129%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000932 %(-$0.02)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.00093%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02129 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000932 %
  (-$0.02)

Key Stats

• Prev. Close: 46.93
• Open: 46.1
• 1-Year Change: 15.45%
• Day's Range: 46.1 - 47.84

Trade Vericel Corp - VCEL

About Vericel Corp

Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).

Equity composition

Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.